title: Protective effect of octreotide and infliximab in an experimental model of indomethacin-induced inflammatory bowel disease.
abstract: Indomethacin administration in animals increases permeability of the small intestine, leading to inflammation that mimics Crohn's disease. Nonsteroidal anti-inflammatory drugs increase the permeability of the intestinal epithelial barrier and should therefore be used with caution in patients with Crohn's disease. We analyzed the protective effects of octreotide and the tumor necrosis factor-alpha inhibitor infliximab in a rat model of indomethacin-induced enterocolitis. Male Wistar rats received 20 mg of infliximab or 10 mug of octreotide 24 h prior to injection with indomethacin. Intestinal permeability was analyzed using Cr-51-ethylenediaminetetraacetic acid clearance. No microscopic or macroscopic alterations were observed in the rats receiving infliximab or octreotide, both of which increased permeability (P < 0.001 versus controls). Our macroscopic and microscopic findings might be related to the low specificity of infliximab and suggest that cytokines affect the intestinal epithelial barrier, as evidenced by the protective effect that infliximab had on the permeability parameters evaluated.
authors: Universidade de São Paulo, Sao Paulo, Brazil. didia_cury@uol.com.br
authors: Dídia H Bismara
authors: DH
authors: Cury
authors: José Edson
authors: JE
authors: Costa
authors: Kioshi
authors: K
authors: Irika
authors: Luciana
authors: L
authors: Mijji
authors: Alessandre
authors: A
authors: Garcez
authors: Carlos
authors: C
authors: Buchiguel
authors: Ivani
authors: I
authors: Silva
authors: Aytan
authors: A
authors: Sipahi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D002463:Cell Membrane Permeability / Q000187:drug effects; D003424:Crohn Disease / Q000139:chemically induced / Q000517:prevention & control; D004195:Disease Models, Animal; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D007213:Indomethacin; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008297:Male; D015282:Octreotide / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab; D015282:Octreotide; D007213:Indomethacin